Best Practices in Melanoma Immunotherapy - prIME Oncology

Best Practices in Melanoma Immunotherapy

Webcast From Immuno-Oncology Virtual Grand Rounds

Not a member of My prIME? Join now for instant access.

Did you miss the live broadcast? Stay engaged in recent updates and key findings in melanoma immuno-oncology with this webcast from our virtual grand rounds series.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



1.0 AMA PRA Category 1 Credit

Release Date

Release Date

Aug 13, 2018

Expiration Date

Aug 13, 2019

Best Practices in Melanoma Immunotherapy
Dirk Schadendorf, MD

  • Dirk Schadendorf, MDUniversity Hospital Essen
    Essen, Germany

This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer, melanoma, or bladder cancer.

After successful completion of this educational activity, participants should be able to:

  • Examine the evidence for the role of biomarkers in immuno-oncology and how to apply them in clinical practice
  • Select optimal immunotherapy approach for patients with cancer
  • Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents
  • Develop strategies to recognize and manage adverse events resulting from the use of immunotherapies

Update on Immunotherapy in NSCLC

Immunotherapy in Lung Cancer: The News From Major Lung Conferences in 2018
Benjamin Besse, MD, PhD

A Practical Application of Data in Bladder Cancer Immunotherapy

Ronald de Wit, MD, PhD

This educational activity is supported by a grant from Merck Sharp and Dohme Corp.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Update on Immunotherapy in NSCLC

prIME Oncology designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the post-test are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Schadendorf has disclosed that he was a board member for BMS, Incyte, MSD, Merck-Serono, Novartis, Pierre Fabre, and Roche. He also received consulting fees from 4SC, BMS, Incyte, MSD, Merck-Serono, Mologen, NeraCare, Novartis, Philogen, Pierre Fabre, and Roche. He received honoraria for promotional speaker’s bureaus from BMS, MSD, and Novartis. Furthermore, he was an independent contractor for BMS and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.